Citations

Clear

1792 citation(s) found for "Stephanie".

Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Becerra, Carlos, Stephenson, Joe , Jonker, Derek J. , Cohn, Allen Lee, Asmis, Timothy R., Conkling, Paul , Garbo, Lawrence, Lenz, Heinz‐Josef , Richards, Donald , Mikhail, Sameh , Goodwin, Rachel , Yoon, Harry H. , Hume, Stephanie , Hitron, Matthew, Li, Chiang, Bekaii‐Saab, Tanios , Spira, Alexander I.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4069-4069

10.1200/jco.2015.33.15_suppl.4069 Get It

Clinical utility of expanded screening of the KRAS and NRAS genes for Metastatic Colorectal Cancer: Evaluation of the CRC RAScan tumor test as a companion diagnostic to determine efficacy of anti-EGFR therapies.
Peterson, Stephanie, Bevilacqua, Jen, Veys, Stephanie, Rosendale, Vicki, Legendre, B. L. , Bible, Keith C. , Richardson, Katherine Anne, Peterson, Stephanie, Legendre, Benjamin L., Reddi, Honey V.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e12554-e12554

10.1200/jco.2015.33.15_suppl.e12554 Get It

Dynamic discriminant model for predicting respiratory distress at birth based on mass volume ratio in fetuses with congenital lung malformation
Eyerly‐Webb, Stephanie A. , Nicolas, Clara T., Watson, D. , Dion, Éric , Amin, Ruchi , Wagner, Amy J., Lampland, Andrea, Bendel‐Stenzel, Ellen , Macardle, C. A., Jorgenson, Alissa , Lillegard, Joseph B. , Feltis, Brad A. , Eyerly-Webb, S , Feltis, B , Watson, D., Kunisaki, Shaun Michael

Mayo Clinic

Ultrasound in Obstetrics & Gynecology | March 5, 2019 | Volume: 54 | Issue: 6 | Pages: 759-766

10.1002/uog.20255 | PMID 30834623 Get It

ABSTRACTObjectivesThe congenital lung malformation volume ratio (CVR) is a prenatal ultrasound measurement that parameterizes congenital lung malformation (CLM) size. The aims of this study were to use serial measurements to create estimated growth curves of fetal CVR for asymptomatic and symptomatic neonates with CLM and to investigate whether a discriminant prognostic model based on these measurements could predict accurately which fetuses with CLM will require invasive respiratory support at delivery and should therefore be delivered at a tertiary‐care facility.MethodsThis was a retrospective study of fetuses diagnosed prenatally with CLM at three tertiary‐care children's hospitals between 2009 and 2016. Those with two or more sonographic measurements of CVR were included. Serial fetal CVR measurements were used to create estimated growth curves for neonates with and those without respiratory symptoms at delivery, defined as requiring invasive respiratory support for the first 24 h after delivery. A discriminant model based on serial CVR measurements was used to calculate the dynamic probability of the need for invasive respiratory support. The performance of this model overall and in preterm and term neonates was compared with those using maximum CVR thresholds of 1.0 and 1.6.ResultsOf the 147 neonates meeting the inclusion criteria, 16 (10.9%) required postnatal invasive respiratory support. The estimated CVR growth curve models showed different growth trajectories for asymptomatic and symptomatic neonates, with significantly higher CVR in symptomatic neonates, and values peaking late in the second trimester at around 25 weeks' gestation in asymptomatic neonates. All prognostic methods had high accuracy for the prediction of the need for invasive respiratory support in term neonates, but the discriminant model had the best performance overall (area under the receiver–operating characteristics curve (AUC) = 0.88) and in the preterm population (AUC = 0.85).ConclusionsThe estimated CVR growth curves showed different growth patterns in asymptomatic and symptomatic neonates with CLM. The dynamic discriminant model performed well overall and particularly in neonates that were carried to term. Development of an externally validated clinical tool based on this analysis could be useful in determining the site of delivery for fetuses with CLM. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques
Matchett, William E. , Anguiano-Zarate, Stephanie S., Shelton, Kathryn A. , Nehete, Bharti P. , Yang, Guojun , Dorta‐Estremera, Stephanie , Barnette, Philip , Xiao, Peng , Villinger, François , Hessell, Ann J. , Haigwood, Nancy L. , Barry, Michael A. , Barry, Michael A , Nehete, Pramod N. , Byrareddy, Siddappa N. , Sastry, K. Jagannadha

Mayo Clinic

Journal of Virology | March 4, 2019 | Volume: 93 | Issue: 10 | Pages: No page available

10.1128/jvi.02016-18 | PMID 30842321 Get It

HIV-1 infections usually start at a mucosal surface after sexual contact. Creating a barrier of protection at these mucosal sites may be a good strategy for to protect against HIV-1 infections. While HIV-1 enters at mucosa, most vaccines are not delivered here. Most are instead injected into the muscle, a site well distant and functionally different than mucosal tissues. This study tested if delivering HIV vaccines at mucosa or in the muscle makes a difference in the quality, quantity, and location of immune responses against the virus. These data suggest that there are indeed advantages to educating the immune system at mucosal sites with an HIV-1 vaccine.
Haplotype-resolved and integrated genome analysis of the cancer cell line HepG2
Zhou, Bo , Ho, Steve S. , Greer, Stephanie , Spies, Noah , Bell, John , Zhang, Xianglong , Zhu, Xiaowei , Arthur, Joseph G. , Byeon, Seunggyu , Pattni, Reenal , Saha, Ishan , Huang, Yi‐Ling , Song, Giltae , Wong, Wing Hung , Ji, Hanlee P. , Abyzov, Alexej , Urban, Alexander E. , Zhou, Bo , Abyzov, Alexej , Perrin, Dimitri

Mayo Clinic

Nucleic Acids Research | March 1, 2019 | Volume: 47 | Issue: 8 | Pages: 3846-3861

10.1093/nar/gkz169 | PMID 30864654 Get It

Care Transitions Program for High‐Risk Frail Older Adults is Most Beneficial for Patients with Cognitive Impairment
Naessens, James M. , Hanson, Gregory J. , Hickson, LaTonya J. , Chen, Christina Y.Y., Rahman, Parvez, Shah, Nilay D. , Borkenhagen, Lynn S., Chandra, Anupam , Havyer, Rachel D. , Leppin, Aaron L. , Thorsteinsdottir, Bjorg , Peterson, Stephanie M, Chen, Christina Yy, Rahman, Parvez A, Borkenhagen, Lynn, Havyer, Rachel, Leppin, Aaron, Takahashi, Paul Y. , Hickson, LaTonya J , Peterson, Stephanie M, McCoy, Rozalina G. , Hanson, Gregory J

Mayo Clinic

Journal of Hospital Medicine | March 1, 2019 | Volume: 14 | Issue: 6 | Pages: 329-335

10.12788/jhm.3112 | PMID 30794142 Get It

BACKGROUNDAlthough posthospitalization care transitions programs (CTP) are highly diverse, their overall program thoroughness is most predictive of their success.OBJECTIVETo identify components of a successful homebased CTP and patient characteristics that are most predictive of reduced 30‐day readmissions.DESIGNRetrospective cohort.PATIENTSA total of 315 community‐dwelling, hospitalized, older adults (≥60 years) at high risk for readmission (Elder Risk Assessment score ≥16), discharged home over the period of January 1, 2011 to June 30, 2013.SETTINGMidwest primary care practice in an integrated health system.INTERVENTIONEnrollment in a CTP during acute hospitalization.MEASUREMENTSThe primary outcome was all‐cause readmission within 30 days of the first CTP evaluation. Logistic regression was used to examine independent variables, including patient demographics, comorbidities, number of medications, completion, and timing of program fidelity measures, and prior utilization of healthcare.RESULTSThe overall 30‐day readmission rate was 17.1%. The intensity of follow‐up varied among patients, with 17.1% and 50.8% of the patients requiring one and ≥3 home visits, respectively, within 30 days. More than half (54.6%) required visits beyond 30 days. Compared with patients who were not readmitted, readmitted patients were less likely to exhibit cognitive impairment (29.6% vs 46.0%; P = .03) and were more likely to have high medication use (59.3% vs 44.4%; P = .047), more emergency department (ED; 0.8 vs 0.4; P = .03) and primary care visits (4.0 vs 3.0; P = .018), and longer cumulative time in the hospital (4.6 vs 2.5 days; P = .03) within 180 days of the index hospitalization. Multivariable analysis indicated that only cognitive impairment and previous ED visits were important predictors of readmission.CONCLUSIONSNo single CTP component reliably predicted reduced readmission risk. Patients with cognitive impairment and polypharmacy derived the most benefit from the program.
SLC35A2‐CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals
Sosicka, Paulina , Agadi, Satish , Almannai, Mohammed , Bacino, Carlos A. , Barone, Rita , Burton, Jennifer, Carlston, Colleen M. , Cohen, Julie S. , Coman, David , Dipple, Katrina M. , Dorrani, Naghmeh, Dobyns, William B. , Elias, Abdallah F. , Epstein, Leon G. , Gahl, William A. , Garozzo, Domenico , Hammer, Trine Bjørg , Haven, Jaclyn, Héron, Delphine, Herzog, Matthew , Hoganson, George, Hunter, Jesse M. , Jain, Mahim , Juusola, Jane, Lakhani, Shenela , Lee, Hane , Lewis, Katherine, Mak, Christopher Chun Yu , McKnight, Dianalee , Mendelsohn, Bryce A. , Mignot, Cyril , Mirzaa, Ghayda , Mitchell, Wendy G. , Muhle, Hiltrud, Nelson, Stanley F. , Olczak, Mariusz , Palmer, Christina G.S. , Partikian, Arthur , Pierson, Tyler Mark , Regan, Brigid M. , Sacoto, María J. Guillen , Scaglia, Fernando , Scheffer, Ingrid E. , Segal, Devorah , Singhal, Nilika S. , Striano, Pasquale, Sturiale, Luisa , Symonds, Joseph D. , Willis, Mary , Wolfe, Lynne A. , Yano, Shoji , Powis, Zöe , Suchy, Sharon F., Edmondson, Andrew C. , Grünewald, Stephanie , Longo, Nicola , Mak, Christopher C Y , Patterson, Marc C. , Ross, M Elizabeth , Scheffer, Ingrid E , Symonds, Joseph , Edmondson, Andrew C , Ng, Bobby G. , Botto, Lorenzo D. , Chung, Hon-Yin B , Juusola, Jane , Lee, Joy Li-Yueh , Lewis, Katherine, Lourenco, Charles , Quinonez, Shane C. , Tang, Sha , Vilain, Eric J. N. , Yang, Hui , Rosenfeld, Jill A. , Freeze, Hudson H.

Mayo Clinic

Human Mutation | February 28, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/humu.23731 | PMID 30817854 Get It

Venous thromboembolic events in patients undergoing craniotomy for tumor resection: incidence, predictors, and review of literature
Rinaldo, Lorenzo , Bhargav, Adip G. , Rusheen, Aaron E. , Naylor, Ryan M. , Gilder, Hannah E., Monie, Dileep D. , Youssef, Stephanie J. , Brown, Desmond A., Monie, Dileep D , Brown, Desmond , Parney, Ian F.

Mayo Clinic

Journal of Neurosurgery | February 27, 2019 | Volume: 132 | Issue: 1 | Pages: 10-21

10.3171/2018.7.jns181175 | PMID 30611138 Get It

OBJECTIVEThe authors sought to investigate the incidence and predictors of venous thromboembolic events (VTEs) after craniotomy for tumor resection, which are not well established, and the efficacy of and risks associated with VTE chemoprophylaxis, which remains controversial.METHODSThe authors investigated the incidence of VTEs in a consecutive series of patients presenting to the authors’ institution for resection of an intracranial lesion between 2012 and 2017. Information on patient and tumor characteristics was collected and independent predictors of VTEs were determined using stepwise multivariate logistic regression analysis. Review of the literature was performed by searching MEDLINE using the keywords “venous thromboembolism,” “deep venous thrombosis,” “pulmonary embolism,” “craniotomy,” and “brain neoplasms.”RESULTSThere were 1622 patients included for analysis. A small majority of patients were female (52.6%) and the mean age of the cohort was 52.9 years (SD 15.8 years). A majority of intracranial lesions were intraaxial (59.3%). The incidence of VTEs was 3.0% and the rates of deep venous thromboses and pulmonary emboli were 2.3% and 0.9%, respectively. On multivariate analysis, increasing patient age (unit OR 1.02, 95% CI 1.00–1.05; p = 0.018), history of VTE (OR 7.26, 95% CI 3.24–16.27; p < 0.001), presence of motor deficit (OR 2.64, 95% CI 1.43–4.88; p = 0.002), postoperative intracranial hemorrhage (OR 4.35, 95% CI 1.51–12.55; p < 0.001), and prolonged intubation or reintubation (OR 3.27, 95% CI 1.28–8.32; p < 0.001) were independently associated with increased odds of a VTE. There were 192 patients who received VTE chemoprophylaxis (11.8%); the mean postoperative day of chemoprophylaxis initiation was 4.6 (SD 3.8). The incidence of VTEs was higher in patients receiving chemoprophylaxis than in patients not receiving chemoprophylaxis (8.3% vs 2.2%; p < 0.001). There were 30 instances of clinically significant postoperative hemorrhage (1.9%), with only 1 hemorrhage occurring after initiation of VTE chemoprophylaxis (0.1%).CONCLUSIONSThe study results show the incidence and predictors of VTEs after craniotomy for tumor resection in this patient population. The incidence of VTE within this cohort appears low and comparable to that observed in other institutional series, despite the lack of routine prophylactic anticoagulation in the postoperative setting.
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Mossé, Yaël P. , Fox, Elizabeth , Hall, David , Safgren, Stephanie L. , Carol, Hernán, Lock, Richard B. , Houghton, Peter J. , Smith, Malcolm A. , Barkauskas, Donald A. , Krailo, Mark , Voss, Stephan D. , Blaney, Susan M. , Weigel, Brenda J. , Teachey, David T. , Teachey, David T , Reid, Joel M. , Smith, Malcolm A , Berg, Stacey L , Safgren, Stephanie L , Berg, Stacey L.

Mayo Clinic

Clinical Cancer Research | February 18, 2019 | Volume: 25 | Issue: 11 | Pages: 3229-3238

10.1158/1078-0432.ccr-18-2675 | PMID 30777875 Get It

Abstract Purpose: Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor activity was observed in neuroblastoma, acute lymphoblastic leukemia, and sarcoma xenografts. We conducted a phase 2 trial of alisertib in pediatric patients with refractory or recurrent solid tumors or acute leukemias (NCT01154816). Patients and Methods: Alisertib (80 mg/m2/dose) was administered orally, daily for 7 days every 21 days. Pharmacogenomic (PG) evaluation for polymorphisms in the AURK gene and drug metabolizing enzymes (UGT1A1*28), and plasma pharmacokinetic studies (PK) were performed. Using a 2-stage design, patients were enrolled to 12 disease strata (10 solid tumor and 2 acute leukemia). Response was assessed after cycle 1, then every other cycle. Results: A total of 139 children and adolescents (median age, 10 years) were enrolled, 137 were evaluable for response. Five objective responses were observed (2 complete responses and 3 partial responses). The most frequent toxicity was myelosuppression. The median alisertib trough concentration on day 4 was 1.3 μmol/L, exceeding the 1 μmol/L target trough concentration in 67% of patients. No correlations between PG or PK and toxicity were observed. Conclusions: Despite alisertib activity in pediatric xenograft models and cogent pharmacokinetic-pharmacodynamic relationships in preclinical models and adults, the objective response rate in children and adolescents receiving single-agent alisertib was less than 5%.